Bausch Health Companies Management
Management criteria checks 2/4
Bausch Health Companies' CEO is Tom Appio, appointed in May 2022, has a tenure of 2.58 years. total yearly compensation is $15.88M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $3.33M. The average tenure of the management team and the board of directors is 2.6 years and 8.4 years respectively.
Key information
Tom Appio
Chief executive officer
US$15.9m
Total compensation
CEO salary percentage | 7.4% |
CEO tenure | 2.6yrs |
CEO ownership | 0.1% |
Management average tenure | 2.6yrs |
Board average tenure | 8.4yrs |
Recent management updates
Recent updates
Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors
Dec 03There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise
Oct 10Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
Sep 19Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%
Aug 062 Red Alerts On Bausch Health Companies
Jul 25The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%
May 21Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results
May 07Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation
Feb 24Bausch Health: $20bn Debt Is A Mighty Elephant In The Room
Nov 30Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?
Nov 01Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics
Sep 24Is Bausch Health Companies (NYSE:BHC) A Risky Investment?
Jul 24Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes
Jul 06What To Do After Bausch Health Stock Plunged By Nearly 9% Again
Jun 07Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt
Apr 18Bausch Health: A Basket Case Of A Business Only A Hedge Fund Can Bail Out
Dec 30Bausch Health acne lotion Arazlo available in Canada under public drug plans
Dec 22Bausch Health: Things To Consider Before Investing
Dec 11Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues
Nov 10Bausch Health Companies Q3 2022 Earnings Preview
Nov 02CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$178m |
Jun 30 2024 | n/a | n/a | -US$471m |
Mar 31 2024 | n/a | n/a | -US$455m |
Dec 31 2023 | US$16m | US$1m | -US$592m |
Sep 30 2023 | n/a | n/a | -US$963m |
Jun 30 2023 | n/a | n/a | -US$186m |
Mar 31 2023 | n/a | n/a | -US$357m |
Dec 31 2022 | US$13m | US$1m | -US$225m |
Sep 30 2022 | n/a | n/a | US$254m |
Jun 30 2022 | n/a | n/a | US$43m |
Mar 31 2022 | n/a | n/a | -US$407m |
Dec 31 2021 | US$10m | US$854k | -US$948m |
Sep 30 2021 | n/a | n/a | -US$1b |
Jun 30 2021 | n/a | n/a | -US$1b |
Mar 31 2021 | n/a | n/a | -US$1b |
Dec 31 2020 | US$4m | US$775k | -US$560m |
Sep 30 2020 | n/a | n/a | -US$2b |
Jun 30 2020 | n/a | n/a | -US$2b |
Mar 31 2020 | n/a | n/a | -US$2b |
Dec 31 2019 | US$4m | US$769k | -US$2b |
Sep 30 2019 | n/a | n/a | -US$616m |
Jun 30 2019 | n/a | n/a | -US$917m |
Mar 31 2019 | n/a | n/a | -US$2b |
Dec 31 2018 | US$4m | US$730k | -US$4b |
Sep 30 2018 | n/a | n/a | -US$3b |
Jun 30 2018 | n/a | n/a | -US$2b |
Mar 31 2018 | n/a | n/a | -US$805m |
Dec 31 2017 | US$3m | US$650k | US$2b |
Compensation vs Market: Tom's total compensation ($USD15.88M) is above average for companies of similar size in the US market ($USD6.57M).
Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.
CEO
Tom Appio (62 yo)
2.6yrs
Tenure
US$15,878,578
Compensation
Mr. Thomas J. Appio, also known as Tom, serves as the Chief Executive Officer & Director at Bausch Health Companies Inc. and served as Chief Executive Officer of Pharma Business and served as President & C...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 2.6yrs | US$15.88m | 0.12% $ 3.3m | |
Executive VP & General Counsel | 2.6yrs | US$3.16m | 0.030% $ 855.6k | |
Executive VP & CFO | less than a year | no data | no data | |
Executive VP & COO | 2.9yrs | no data | 0.036% $ 1.0m | |
VP & Head of Investor Relations | no data | no data | no data | |
Executive VP and Chief HR & Communications Officer | 2.9yrs | no data | no data | |
Senior Vice President of Europe & Canada | 2.9yrs | no data | no data | |
Senior Vice President of Ortho Dermatologics | no data | no data | no data | |
Senior Vice President of Solta Medical | 1.9yrs | no data | no data | |
Executive Vice President of US Pharma | less than a year | no data | no data | |
Executive VP | no data | no data | no data | |
Senior VP & Treasurer | no data | no data | no data |
2.6yrs
Average Tenure
55yo
Average Age
Experienced Management: BHC's management team is considered experienced (2.6 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 2.6yrs | US$15.88m | 0.12% $ 3.3m | |
Independent Chairman | 2.5yrs | US$812.50k | 0.000060% $ 1.7k | |
Independent Director | 16.3yrs | US$389.55k | 0.0018% $ 50.4k | |
Chairman of External Advisory Board | no data | US$2.00m | no data | |
Independent Director | 8.4yrs | US$718.28k | 0% $ 0 | |
Member of the External Advisory Board | 15.8yrs | no data | no data | |
Member of the External Advisory Board | 15.8yrs | no data | no data | |
Member of the External Advisory Board | 15.8yrs | no data | no data | |
Independent Director | 3.8yrs | US$691.72k | 0.00020% $ 5.6k | |
Independent Director | 8.5yrs | US$377.50k | 0.011% $ 322.4k | |
Independent Director | 3.8yrs | US$381.31k | 0.031% $ 863.5k | |
Independent Director | less than a year | no data | no data |
8.4yrs
Average Tenure
67yo
Average Age
Experienced Board: BHC's board of directors are considered experienced (8.4 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/17 06:13 |
End of Day Share Price | 2024/12/17 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bausch Health Companies Inc. is covered by 46 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Raghuram Selvaraju | Aegis Capital Corporation |
Douglas Tsao | Barclays |
Ardalan Arfaei | BMO Capital Markets Equity Research |